These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 20685764)

  • 1. The management of multiple sclerosis in children: a European view.
    Ghezzi A; Banwell B; Boyko A; Amato MP; Anlar B; Blinkenberg M; Boon M; Filippi M; Jozwiak S; Ketelslegers I; Kornek B; Lim M; Lindstrom E; Nadj C; Neuteboom R; Rocca MA; Rostasy K; Tardieu M; Wassmer E; Catsman-Berrevoets C; Hintzen R
    Mult Scler; 2010 Oct; 16(10):1258-67. PubMed ID: 20685764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapy of multiple sclerosis in children and adolescents.
    Tenembaum SN
    Clin Neurol Neurosurg; 2010 Sep; 112(7):633-40. PubMed ID: 20471159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
    Schwid SR; Panitch HS
    Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Immunomodulatory therapy in multiple sclerosis].
    Csépány T; Bereczki D
    Ideggyogy Sz; 2004 Nov; 57(11-12):401-16. PubMed ID: 15662768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
    Jacobs LD; Cookfair DL; Rudick RA; Herndon RM; Richert JR; Salazar AM; Fischer JS; Goodkin DE; Granger CV; Simon JH; Alam JJ; Bartoszak DM; Bourdette DN; Braiman J; Brownscheidle CM; Coats ME; Cohan SL; Dougherty DS; Kinkel RP; Mass MK; Munschauer FE; Priore RL; Pullicino PM; Scherokman BJ; Whitham RH
    Ann Neurol; 1996 Mar; 39(3):285-94. PubMed ID: 8602746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What can be learned from open direct comparative trials in multiple sclerosis?
    Khan O
    J Neurol Sci; 2009 Feb; 277 Suppl 1():S25-8. PubMed ID: 19200861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natalizumab: new drug. Multiple sclerosis: risky market approval.
    Prescrire Int; 2008 Feb; 17(93):7-10. PubMed ID: 18354844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple sclerosis: interferon beta for some serious forms.
    Prescrire Int; 2007 Dec; 16(92):252-7. PubMed ID: 18092425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical surveillance of patients with multiple sclerosis].
    Cazzato G; Zorzon M
    Recenti Prog Med; 2003 Apr; 94(4):173-6. PubMed ID: 12677789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [MS Therapy Consensus Group. Immunomodulating staged therapy of multiple sclerosis].
    Nervenarzt; 1999 Apr; 70(4):371-86. PubMed ID: 10355003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disease-modifying drugs for the early treatment of multiple sclerosis.
    Flachenecker P
    Expert Rev Neurother; 2004 May; 4(3):455-63. PubMed ID: 15853542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of early onset multiple sclerosis with suboptimal dose of interferon beta-1a.
    Pakdaman H; Fallah A; Sahraian MA; Pakdaman R; Meysamie A
    Neuropediatrics; 2006 Aug; 37(4):257-60. PubMed ID: 17177154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PRISMS: the story of a pivotal clinical trial series in multiple sclerosis.
    Cohen BA; Rivera VM
    Curr Med Res Opin; 2010 Apr; 26(4):827-38. PubMed ID: 20121658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ
    Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of children and adolescents with multiple sclerosis.
    Banwell B
    Expert Rev Neurother; 2005 May; 5(3):391-401. PubMed ID: 15938672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lessons from randomised direct comparative trials.
    Achiron A; Fredrikson S
    J Neurol Sci; 2009 Feb; 277 Suppl 1():S19-24. PubMed ID: 19200860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical effects and tolerability of high-dose, high-frequency recombinant interferon beta-1a in patients with multiple sclerosis: maximizing therapy through long-term adherence.
    Boyko AN
    Expert Opin Biol Ther; 2010 Apr; 10(4):653-66. PubMed ID: 20218924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon beta: the current position.
    Boothman BR
    Br J Hosp Med; 1997 Mar 19-Apr 1; 57(6):277-80. PubMed ID: 9196574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant human interferon beta in the treatment of relapsing-remitting and secondary progressive multiple sclerosis.
    Sandberg-Wollheim M; Hommes OR; Hughes RA; Paty DW; Abdul-Ahad AK
    Mult Scler; 1995; 1 Suppl 1():S48-50. PubMed ID: 9345399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Interferon therapy of multiple sclerosis].
    Jensen D
    Tidsskr Nor Laegeforen; 1999 Sep; 119(21):3142-5. PubMed ID: 10522481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.